Mayo Clinic Q and A: Primary Hyperparathyroidism Typically Doesn’t Cause Early Symptoms
DEAR MAYO CLINIC: After a routine blood test my doctor called and said that I have higher than normal levels of calcium in my blood. He wants me to come back for another appointment to test for something called primary hyperparathyroidism. What causes this condition, and is it treatable? I am 60 and always have [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 1, 2016 Category: Databases & Libraries Source Type: news
Etelcalcetide (calcimimetic) for the Treatment of Secondary Hyperparathyroidism (SHPT)
Etelcalcetide (formerly AMG416), an intravenous injectable calcimimetic agent, is currently under development by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on haemodialysis. (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2016 Category: Pharmaceuticals Source Type: news
Surgery is more effective than drug in hyperparathyroidism post-kidney transplantation
A new study compared the results of surgery with drug therapy in patients with tertiary hyperparathyroidism, i.e., after a kidney transplant. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 16, 2015 Category: Science Source Type: news
Quantitation of Parathyroid Hormone in Serum or Plasma by Liquid Chromatography-Tandem Mass Spectrometry
Parathyroid hormone (PTH), an 84 amino acid peptide hormone, is an important regulator of calcium homeostasis. Quantitation of PTH in serum is useful for the diagnosis of primary hyperparathyroidism, hypoparathyroidism, and for monitoring osteodystrophy in patients with renal failure. The biological activity of PTH arises from binding of PTH (N terminus) to its target receptor (D’Amour et al., Kidney Int 68: 998–1007, 2005). Several C-terminal and N-terminal fragments circulate in normal subjects. Recent studies have demonstrated that accurate quantitation of PTH fragments may be of clinical value. In this chap...
Source: Springer protocols feed by Imaging/Radiology - November 27, 2015 Category: Radiology Source Type: news
Multiple fractures in a 22-year-old man after a simple fall - Alattas MH, Dimentberg R.
We present the case of a 22-year-old male with longstanding progressive fatigue, weakness and pain around his hips due to an undiagnosed parathyroid adenoma. The resultant primary hyperparathyroidism ultimately caused pathologic fractures. He was admitted ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - October 11, 2015 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Amgen files for FDA approval for drug to treat dialysis patients
Amgen Inc. said it has filed for approval to sell its drug to treat patients with chronic kidney disease on dialysis.
Thousand Oaks-based Amgen(Nasdaq: AMGN) said it submitted a new drug application to the U.S. Food and Drug Administration for etelcalcetide, formerly AMG 416, for the treatment of secondary hyperparathyroidism, a condition that can cause fragile bones, bone pain and organ damage.
If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 26, 2015 Category: American Health Source Type: news
Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate.
The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - July 28, 2015 Category: Hospital Management Authors: Brian Bandell Source Type: news
Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate.
The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2015 Category: Biotechnology Authors: Brian Bandell Source Type: news
Parathyroidectomy Rarely Used in Renal-Transplant PatientsParathyroidectomy Rarely Used in Renal-Transplant Patients
A single-center study finds parathyroidectomy used in only 6.6% of kidney-transplant patients with postsurgical hyperparathyroidism, but when used it provides benefit and doesn't harm the kidney graft. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 3, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Erectile Dysfunction May Resolve With ParathyroidectomyErectile Dysfunction May Resolve With Parathyroidectomy
Pilot data suggest that men with primary hyperparathyroidism who report erectile dysfunction prior to parathyroidectomy may experience improvement in erectile function following surgery. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 21, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Amgen Drug Shows Positive Results in Late-Phase Study
A late-phase clinical study of Amgen Inc.’s experimental treatment for secondary hyperparathyroidism in patients with chronic kidney disease showed a higher percentage of patients responded to its treatment. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 25, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news
Competencies added to Society for Endocrinology Competency Framework for Adult Endocrine Nursing
An updated Competency Framework for adult endocrine nursing has been developed to standardise and improve the quality of care for patients with hormone related diseases. The framework is published this week in the journal Endocrine Connections and builds upon the original Competency Framework for Adult Endocrine Nursing which was published by the Society for Endocrinology in 2013.
This document is the product of extensive collaboration between nurses working in adult endocrinology. The competencies are easily transferable and should help nurses working both at home and abroad to develop as professional practitio...
Source: Society for Endocrinology - February 10, 2015 Category: Endocrinology Source Type: news
Silent Renal Stones in Primary HyperparathyroidismSilent Renal Stones in Primary Hyperparathyroidism
Should patients with hyperparathyroidism be screened for nephrolithiasis? What if they're asymptomatic? Endocrine Practice (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - January 2, 2015 Category: Urology & Nephrology Tags: Diabetes & Endocrinology Journal Article Source Type: news
Primary hyperparathyroidism due to cystic adenoma
This report describes the usefulness of PTH–FNA for localizing and differentiating an atypical functional parathyroid lesion from nonfunctional tissue in primary hyperparathyroidism. They suggest that if not contraindicated, PTH–FNA could be helpful in the differential diagnosis of equivocal cervical tumors.
Read full Case at Kawashima et al. (2014), Endocrinology, Diabetes & Metabolism Case Reports, DOI: 10.1530/EDM-14-0086 (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 25, 2014 Category: Endocrinology Source Type: news
Mother who looked 9 months pregnant discovers her condition online as hyperparathyroidism
EXC: Sallie Powell. 47, from Derby, said until diagnosing herself with hyperparathyroidism, the excruciating pains in her joints and overwhelming tiredness had forced her to give up work. (Source: the Mail online | Health)
Source: the Mail online | Health - October 3, 2014 Category: Consumer Health News Source Type: news
